In this issue:
Paclitaxel and carboplatin vs BEP for chemotherapy-naïve ovarian SCST
Close monitoring for two years after initial treatment of OCCC may be optimal
BRCA1/2 mutation type and location impacts survival in PSROC on olaparib
Does secondary cytoreduction for PSROC improve survival?
Green tea linked to improved outcomes in women with ovarian cancer
Stereotactic radiotherapy + PARP inhibition feasible for oligoprogression
Effectiveness of chemotherapy after progression during PARP inhibition
Good prognosis in HGSOC patients with concurrent RB1 loss + BRCA deficiency
ANITA: no benefit to atezolizumab + chemotherapy in recurrent disease
Please login below to download this issue (PDF)